|
1
|
Whelan J, McTiernan A, Cooper N, Wong YK,
Francis M, Vernon S and Strauss SJ: Incidence and survival of
malignant bone sarcomas in England 1979–2007. Int J Cancer.
131:E508–E517. 2012. View Article : Google Scholar
|
|
2
|
Sakamoto A and Iwamoto Y: Current status
and perspectives regarding the treatment of osteo-sarcoma:
Chemotherapy. Rev Recent Clin Trials. 3:228–231. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allison DC, Carney SC, Ahlmann ER,
Hendifar A, Chawla S, Fedenko A, Angeles C and Menendez LR: A
meta-analysis of osteosarcoma outcomes in the modern medical era.
Sarcoma. 2012:7048722012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miller BJ, Cram P, Lynch CF and Buckwalter
JA: Risk factors for metastatic disease at presentation with
osteosarcoma: An analysis of the SEER database. J Bone Joint Surg
Am. 95:e892013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qiu H, Fang X, Luo Q and Ouyang G: Cancer
stem cells: A potential target for cancer therapy. Cell Mol Life
Sci. 72:3411–3424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tirino V, Desiderio V, d'Aquino R, De
Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De
Rosa A, Papaccio G, et al: Detection and characterization of
CD133+ cancer stem cells in human solid tumours. PLoS
One. 3:e34692008. View Article : Google Scholar
|
|
8
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, Fazioli F, Pirozzi G and Papaccio G: Human primary bone
sarcomas contain CD133+ cancer stem cells displaying
high tumorigenicity in vivo. FASEB J. 25:2022–2030. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li
JM, Yang T and Liu W: CD133 expression in osteosarcoma and
derivation of CD133+ cells. Mol Med Rep. 7:577–584.
2013.
|
|
10
|
Li X, Tian J, Bo Q, Li K, Wang H, Liu T
and Li J: Targeting DNA-PKcs increased anticancer drug sensitivity
by suppressing DNA damage repair in osteosarcoma cell line MG63.
Tumour Biol. 36:9365–9372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tian J, Li X, Si M, Liu T and Li J:
CD271+ osteosarcoma cells display stem-like properties.
PLoS One. 9:e985492014. View Article : Google Scholar
|
|
12
|
Choi BH, Kim CG, Lim Y, Shin SY and Lee
YH: Curcumin downregulates the multidrug-resistance mdr1b gene by
inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett.
259:111–118. 2008. View Article : Google Scholar
|
|
13
|
Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe
S, Mills GB and Unate H: Induction of human MDR1 gene expression by
2-acetylaminofluorene is mediated by effectors of the
phosphoinositide 3-kinase pathway that activate NF-kappaB
signaling. Oncogene. 21:1945–1954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cooke SL, Ng CK, Melnyk N, Garcia MJ,
Hardcastle T, Temple J, Langdon S, Huntsman D and Brenton JD:
Genomic analysis of genetic heterogeneity and evolution in
high-grade serous ovarian carcinoma. Oncogene. 29:4905–4913. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xing J, Wu X, Vaporciyan AA, Spitz MR and
Gu J: Prognostic significance of ataxia-telangiectasia mutated,
DNA-dependent protein kinase catalytic subunit, and Ku
heterodimeric regulatory complex 86-kD subunit expression in
patients with nonsmall cell lung cancer. Cancer. 112:2756–2764.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Willmore E, Elliott SL, Mainou-Fowler T,
Summerfield GP, Jackson GH, O'Neill F, Lowe C, Carter A, Harris R,
Pettitt AR, et al: DNA-dependent protein kinase is a therapeutic
target and an indicator of poor prognosis in B-cell chronic
lymphocytic leukemia. Clin Cancer Res. 14:3984–3992. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fang Y, Chai Z, Wang D, Kuang T, Wu W and
Lou W: DNA-PKcs deficiency sensitizes the human hepatoma HepG2
cells to cisplatin and 5-fluorouracil through suppression of the
PI3K/Akt/NF-κB pathway. Mol Cell Biochem. 399:269–278. 2015.
View Article : Google Scholar
|
|
19
|
Ciszewski WM, Tavecchio M, Dastych J and
Curtin NJ: DNA-PK inhibition by NU7441 sensitizes breast cancer
cells to ionizing radiation and doxorubicin. Breast Cancer Res
Treat. 143:47–55. 2014. View Article : Google Scholar
|
|
20
|
Facchino S, Abdouh M, Chatoo W and Bernier
G: BMI1 confers radioresistance to normal and cancerous neural stem
cells through recruitment of the DNA damage response machinery. J
Neurosci. 30:10096–10111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mimeault M, Hauke R and Batra SK: Recent
advances on the molecular mechanisms involved in the drug
resistance of cancer cells and novel targeting therapies. Clin
Pharmacol Ther. 83:673–691. 2008. View Article : Google Scholar
|
|
22
|
Ye S, Zhang J, Shen J, Gao Y, Li Y, Choy
E, Cote G, Harmon D, Mankin H, Gray NS, et al: NVP-TAE684 reverses
multidrug resistance (MDR) in human osteosarcoma by inhibiting
P-glycoprotein (PGP1) function. Br J Pharmacol. 173:613–626. 2016.
View Article : Google Scholar
|
|
23
|
Yang X, Yang P, Shen J, Osaka E, Choy E,
Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, et al: Prevention
of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J
Cancer. 110:2896–2904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fanelli M, Hattinger CM, Vella S, Tavanti
E, Michelacci F, Gudeman B, Barnett D, Picci P and Serra M:
Targeting ABCB1 and ABCC1 with their specific inhibitor
CBT-1® can overcome drug resistance in osteosarcoma.
Curr Cancer Drug Targets. 16:261–274. 2016. View Article : Google Scholar
|
|
25
|
Martins-Neves SR, Lopes AO, do Carmo A,
Paiva AA, Simões PC, Abrunhosa AJ and Gomes CM: Therapeutic
implications of an enriched cancer stem-like cell population in a
human osteosarcoma cell line. BMC Cancer. 12:1392012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gonçalves C, Martins-Neves SR,
Paiva-Oliveira D, Oliveira VE, Fontes-Ribeiro C and Gomes CM:
Sensitizing osteosarcoma stem cells to doxorubicin-induced
apoptosis through retention of doxorubicin and modulation of
apoptotic-related proteins. Life Sci. 130:47–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang X, Fraser M, Moll UM, Basak A and
Tsang BK: Akt-mediated cisplatin resistance in ovarian cancer:
Modulation of p53 action on caspase-dependent mitochondrial death
pathway. Cancer Res. 66:3126–3136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Molina JR, Hayashi Y, Stephens C and
Georgescu MM: Invasive glioblastoma cells acquire stemness and
increased Akt activation. Neoplasia. 12:453–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wittig-Blaich SM, Kacprzyk LA, Eismann T,
Bewerunge-Hudler M, Kruse P, Winkler E, Strauss WS, Hibst R,
Steiner R, Schrader M, et al: Matrix-dependent regulation of AKT in
Hepsin-overexpressing PC3 prostate cancer cells. Neoplasia.
13:579–589. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou G and Kuo MT: NF-kappaB-mediated
induction of mdr1b expression by insulin in rat hepatoma cells. J
Biol Chem. 272:15174–15183. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun J, Yeung CA, Co NN, Tsang TY, Yau E,
Luo K, Wu P, Wa JC, Fung KP, Kwok TT, et al: Clitocine reversal of
P-glycoprotein associated multi-drug resistance through
down-regulation of transcription factor NF-κB in R-HepG2 cell line.
PLoS One. 7:e407202012. View Article : Google Scholar
|
|
32
|
Zhao BX, Sun YB, Wang SQ, Duan L, Huo QL,
Ren F and Li GF: Grape seed procyanidin reversal of p-glycoprotein
associated multi-drug resistance via down-regulation of NF-κB and
MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One.
8:e710712013. View Article : Google Scholar
|
|
33
|
Xia YZ, Ni K, Guo C, Zhang C, Geng YD,
Wang ZD, Yang L and Kong LY: Alopecurone B reverses
doxorubicin-resistant human osteosarcoma cell line by inhibiting
P-glycoprotein and NF-kappa B signaling. Phytomedicine. 22:344–351.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nomura A, Banerjee S, Chugh R, Dudeja V,
Yamamoto M, Vickers SM and Saluja AK: CD133 initiates tumors,
induces epithelial-mesenchymal transition and increases metastasis
in pancreatic cancer. Oncotarget. 6:8313–8322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu Y, Yu J, Wang S, Lu R, Wu J and Jiang
B: Overexpression of CD133 enhances chemoresistance to
5-fluorouracil by activating the PI3K/Akt/p70S6K pathway in gastric
cancer cells. Oncol Rep. 32:2437–2444. 2014.PubMed/NCBI
|
|
36
|
Xi G, Hayes E, Lewis R, Ichi S,
Mania-Farnell B, Shim K, Takao T, Allender E, Mayanil CS and Tomita
T: CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB
pathway in multidrug-resistant glioblastoma cells in vitro.
Oncogene. 35:241–250. 2016. View Article : Google Scholar
|
|
37
|
Stronach EA, Chen M, Maginn EN, Agarwal R,
Mills GB, Wasan H and Gabra H: DNA-PK mediates AKT activation and
apoptosis inhibition in clinically acquired platinum resistance.
Neoplasia. 13:1069–1080. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Feng J, Park J, Cron P, Hess D and
Hemmings BA: Identification of a PKB/Akt hydrophobic motif Ser-473
kinase as DNA-dependent protein kinase. J Biol Chem.
279:41189–41196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rajagopalan S, Moyle MW, Joosten I and
Long EO: DNA-PKcs controls an endosomal signaling pathway for a
proinflammatory response by natural killer cells. Sci Signal.
3:ra142010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Leslie NR, Biondi RM and Alessi DR:
Phosphoinositide-regulated kinases and phosphoinositide
phosphatases. Chem Rev. 101:2365–2380. 2001. View Article : Google Scholar : PubMed/NCBI
|
